0001400271 2023-01-01 2023-12-31 0001400271 2023-12-31 0001400271 2022-12-31 0001400271 us-gaap:RelatedPartyMember 2023-12-31 0001400271 us-gaap:RelatedPartyMember 2022-12-31 0001400271 us-gaap:NonrelatedPartyMember 2023-12-31 0001400271 us-gaap:NonrelatedPartyMember 2022-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001400271 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001400271 2022-01-01 2022-12-31 0001400271 us-gaap:CommonStockMember 2021-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001400271 us-gaap:RetainedEarningsMember 2021-12-31 0001400271 2021-12-31 0001400271 us-gaap:CommonStockMember 2022-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001400271 us-gaap:RetainedEarningsMember 2022-12-31 0001400271 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001400271 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001400271 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001400271 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001400271 us-gaap:CommonStockMember 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001400271 us-gaap:RetainedEarningsMember 2023-12-31 0001400271 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001400271 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001400271 CUBT:SharesIssuableUponConversionOfSeriesBPreferredStockMember 2023-01-01 2023-12-31 0001400271 CUBT:SharesIssuableUponConversionOfSeriesCPreferredStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001400271 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001400271 CUBT:SharesIssuableUponConversionOfSeriesBPreferredStockMember 2022-01-01 2022-12-31 0001400271 CUBT:SharesIssuableUponConversionOfSeriesCPreferredStockMember 2022-01-01 2022-12-31 0001400271 CUBT:MABTCovidNineteenLicenseMember CUBT:MidAtlanticBioTheraputicsIncMember 2023-01-01 2023-12-31 0001400271 CUBT:MABTCovidNineteenLicenseMember CUBT:MidAtlanticBioTheraputicsIncMember 2023-12-31 0001400271 CUBT:MABTCovidNineteenLicenseMember CUBT:MidAtlanticBioTheraputicsIncMember 2022-04-01 2022-04-30 0001400271 CUBT:MABTCovidNineteenLicenseMember CUBT:MidAtlanticBioTheraputicsIncMember 2022-01-01 2022-12-31 0001400271 CUBT:MABTCovidNineteenLicenseMember CUBT:MidAtlanticBioTheraputicsIncMember 2022-12-31 0001400271 CUBT:WebsiteMember 2020-12-01 2020-12-31 0001400271 CUBT:WebsiteMember 2020-12-31 0001400271 CUBT:WebsiteMember 2023-01-01 2023-12-31 0001400271 CUBT:WebsiteMember 2022-01-01 2022-12-31 0001400271 CUBT:WebsiteMember 2023-12-31 0001400271 CUBT:WebsiteMember 2022-12-31 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2020-10-01 2020-10-31 0001400271 us-gaap:PatentsMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember us-gaap:PatentsMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MaximumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MaximumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MaximumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-10-01 2020-10-31 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2022-03-01 2022-03-31 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2023-01-01 2023-12-31 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2022-01-01 2022-12-31 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2023-12-31 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2022-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseOneMember 2020-10-01 2020-10-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseOneMember 2023-01-01 2023-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseOneMember 2022-01-01 2022-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseOneMember 2023-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseOneMember 2022-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2021-01-01 2021-01-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2023-01-01 2023-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2022-01-01 2022-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2023-12-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2022-12-31 0001400271 CUBT:RoyaltyOneMember CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2021-01-01 2021-01-31 0001400271 CUBT:MABTCovidNineteenLicenseMember 2023-12-31 0001400271 CUBT:MABTCovidNineteenLicenseMember 2022-12-31 0001400271 us-gaap:PatentsMember 2023-12-31 0001400271 us-gaap:PatentsMember 2022-12-31 0001400271 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0001400271 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001400271 CUBT:TwoOfficersMember 2023-01-01 2023-06-30 0001400271 CUBT:TwoOfficersMember 2023-06-30 0001400271 CUBT:TwoOfficersMember 2023-01-01 2023-03-31 0001400271 CUBT:TwoOfficersMember 2023-03-31 0001400271 CUBT:PromissoryNoteExchangeMember 2022-05-26 2022-05-27 0001400271 2023-05-26 2023-05-27 0001400271 2023-05-27 0001400271 2023-12-15 2023-12-16 0001400271 us-gaap:SubsequentEventMember 2024-02-01 2024-02-01 0001400271 us-gaap:SubsequentEventMember 2024-02-01 0001400271 us-gaap:SubsequentEventMember 2024-02-28 2024-02-29 0001400271 us-gaap:SubsequentEventMember 2024-02-29 0001400271 CUBT:TwelveMonthSeniorSecuredNoteMember 2022-03-02 0001400271 CUBT:TwelveMonthSeniorSecuredNoteMember 2022-03-02 2022-03-02 0001400271 CUBT:BeginningInSeptemberTwoThousandAndTwentyTwoMember 2022-01-01 2022-09-30 0001400271 CUBT:BeginningInSeptemberTwoThousandAndTwentyTwoMember 2022-09-30 0001400271 CUBT:FirstModificationMember 2022-08-01 2022-08-31 0001400271 CUBT:FirstModificationMember 2022-09-01 2022-09-01 0001400271 CUBT:FirstModificationMember 2022-08-31 0001400271 CUBT:SecondModificationMember 2022-10-01 2022-10-31 0001400271 CUBT:ThirdModificationMember 2022-10-01 2022-10-31 0001400271 CUBT:ThirdModificationMember CUBT:LenderMember 2022-10-31 0001400271 CUBT:FourthModificationMember 2022-11-01 2022-11-30 0001400271 CUBT:FifthModificationMember 2022-11-01 2022-11-30 0001400271 CUBT:FifthModificationMember CUBT:LenderMember 2022-11-30 0001400271 CUBT:SixthModificationMember 2022-12-02 2022-12-31 0001400271 CUBT:SixthModificationMember CUBT:LenderMember 2022-12-31 0001400271 CUBT:SeventhThroughEleventhModificationMember 2023-01-01 2023-03-31 0001400271 CUBT:TwelfthModificationMember 2023-04-01 2023-06-30 0001400271 CUBT:ThirteenthModificationMember 2023-07-01 2023-09-30 0001400271 CUBT:FourtheenthAndFifteenthModificationMember 2023-10-01 2023-12-31 0001400271 CUBT:FourtheenthAndFifteenthModificationMember 2023-01-01 2023-12-31 0001400271 CUBT:FourtheenthAndFifteenthModificationMember 2022-01-01 2022-12-31 0001400271 CUBT:FourtheenthAndFifteenthModificationMember 2023-12-31 0001400271 CUBT:FourtheenthAndFifteenthModificationMember 2022-12-31 0001400271 2023-10-01 2023-12-31 0001400271 CUBT:ConsultantMember 2023-10-01 2023-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember CUBT:ExchangeForServicesMember 2023-10-01 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember CUBT:ExchangeForServicesMember 2023-07-01 2023-09-30 0001400271 us-gaap:SeriesBPreferredStockMember CUBT:ExchangeForServicesMember 2023-01-01 2023-03-31 0001400271 us-gaap:SeriesBPreferredStockMember CUBT:ExchangeForServicesMember 2022-10-01 2022-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001400271 srt:OfficerMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001400271 CUBT:FormerOfficerMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001400271 CUBT:FormerDirectorMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001400271 CUBT:TwoCurrentOfficerMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001400271 CUBT:ConsultantMember us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001400271 us-gaap:WarrantMember 2023-10-01 2023-12-31 0001400271 us-gaap:WarrantMember 2023-12-31 0001400271 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001400271 CUBT:SeriesCPreferredStockDeemedDividendMember 2023-01-01 2023-03-31 0001400271 2022-10-01 2022-12-31 0001400271 us-gaap:WarrantMember 2022-10-01 2022-12-31 0001400271 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-03-31 0001400271 us-gaap:WarrantMember 2022-12-31 0001400271 us-gaap:WarrantMember 2021-12-31 0001400271 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001400271 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001400271 CUBT:ExercisePriceMember 2023-12-31 0001400271 CUBT:ExercisePriceOneMember 2023-12-31 0001400271 CUBT:ExercisePriceTwoMember 2023-12-31 0001400271 CUBT:ExercisePriceThreeMember 2023-12-31 0001400271 CUBT:ExercisePriceFourMember 2023-12-31 0001400271 CUBT:ExercisePriceFiveMember 2023-12-31 0001400271 CUBT:ExercisePriceSixMember 2023-12-31 0001400271 CUBT:ExercisePriceSevenMember 2023-12-31 0001400271 CUBT:ExercisePriceEightMember 2023-12-31 0001400271 CUBT:ExercisePriceNineMember 2023-12-31 0001400271 CUBT:ExercisePriceTenMember 2023-12-31 0001400271 CUBT:ExercisePriceElevenMember 2023-12-31 0001400271 CUBT:ExercisePriceTwelveMember 2023-12-31 0001400271 CUBT:ExercisePriceThirteenMember 2023-12-31 0001400271 CUBT:ExercisePriceFiveMember 2022-12-31 0001400271 2022-07-01 2022-09-30 0001400271 CUBT:LenderMember us-gaap:WarrantMember 2022-03-02 0001400271 CUBT:LenderMember us-gaap:WarrantMember 2022-03-01 2022-03-02 0001400271 2022-03-01 2022-03-02 0001400271 srt:MinimumMember CUBT:WarrantsMember 2022-03-02 0001400271 srt:MaximumMember CUBT:WarrantsMember 2022-03-02 0001400271 srt:MinimumMember CUBT:WarrantsMember 2022-03-01 2022-03-02 0001400271 srt:MaximumMember CUBT:WarrantsMember 2022-03-01 2022-03-02 0001400271 CUBT:BoardOfAdvisoryMember 2023-10-01 2023-12-31 0001400271 CUBT:BoardOfAdvisoryMember 2023-12-31 0001400271 CUBT:BoardOfAdvisoryMember 2021-07-01 2021-09-30 0001400271 CUBT:BoardOfAdvisoryMember 2021-09-30 0001400271 2021-09-30 0001400271 CUBT:BoardOfAdvisoryMember us-gaap:SubsequentEventMember 2022-09-01 2022-09-30 0001400271 2021-07-01 2021-09-30 0001400271 CUBT:EmployeesMember 2022-01-01 2022-03-31 0001400271 CUBT:EmployeesMember 2022-03-31 0001400271 CUBT:EmployeesMember 2022-01-01 2022-12-31 0001400271 CUBT:EmployeesMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001400271 CUBT:EmployeesMember us-gaap:OptionMember 2022-01-01 2022-12-31 0001400271 2022-10-01 2022-10-31 0001400271 us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2024-01-01 2024-01-31 0001400271 us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2024-01-31 0001400271 us-gaap:StockOptionMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2024-01-01 2024-01-31 0001400271 us-gaap:StockOptionMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2024-01-31 0001400271 CUBT:NotePayableMember us-gaap:SubsequentEventMember 2024-01-01 2024-01-31 0001400271 us-gaap:SubsequentEventMember 2024-02-29 2024-02-29 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2024-03-31 0001400271 us-gaap:SubsequentEventMember 2024-03-31 0001400271 us-gaap:SubsequentEventMember 2024-01-31 0001400271 CUBT:OneVendorMember us-gaap:SubsequentEventMember 2024-03-31 0001400271 us-gaap:SubsequentEventMember 2022-09-26 2022-09-26 0001400271 CUBT:ReverseStockSplitPreSplitBasisMember 2023-01-01 2023-12-31 0001400271 CUBT:ReverseStockSplitPreSplitBasisMember 2022-01-01 2022-12-31 0001400271 CUBT:ReverseStockSplitPostSplitBasisMember 2023-01-01 2023-12-31 0001400271 CUBT:ReverseStockSplitPostSplitBasisMember 2022-01-01 2022-12-31 0001400271 CUBT:ConversionOfSeriesBAndCPreferredStockMember 2023-12-31 0001400271 CUBT:OneToOneThousandFourHundredAdjustmentMember 2023-12-31 0001400271 srt:ProFormaMember 2023-12-31 0001400271 us-gaap:SeriesBPreferredStockMember CUBT:ConversionOfSeriesBAndCPreferredStockMember 2023-12-31 0001400271 CUBT:OneToOneThousandFourHundredAdjustmentMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001400271 srt:ProFormaMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001400271 us-gaap:SeriesCPreferredStockMember CUBT:ConversionOfSeriesBAndCPreferredStockMember 2023-12-31 0001400271 CUBT:OneToOneThousandFourHundredAdjustmentMember us-gaap:SeriesCPreferredStockMember 2023-12-31 0001400271 srt:ProFormaMember us-gaap:SeriesCPreferredStockMember 2023-12-31 0001400271 CUBT:ConversionOfSeriesBAndCPreferredStockMember 2022-12-31 0001400271 CUBT:OneToOneThousandFourHundredAdjustmentMember 2022-12-31 0001400271 srt:ProFormaMember 2022-12-31 0001400271 us-gaap:SeriesBPreferredStockMember CUBT:ConversionOfSeriesBAndCPreferredStockMember 2022-12-31 0001400271 CUBT:OneToOneThousandFourHundredAdjustmentMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001400271 srt:ProFormaMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001400271 us-gaap:SeriesCPreferredStockMember CUBT:ConversionOfSeriesBAndCPreferredStockMember 2022-12-31 0001400271 CUBT:OneToOneThousandFourHundredAdjustmentMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0001400271 srt:ProFormaMember us-gaap:SeriesCPreferredStockMember 2022-12-31 iso4217:USD shares iso4217:USD shares pure CUBT:Integer false 0001400271

P5Y

P10Y

P5Y

S-1 Curative Biotechnology, Inc. FL 2836 26-1412177 3801 PGA Blvd Suite 600 Palm Beach Gardens FL 33410 (561) 907-8990 Non-accelerated Filer true true false

56400

58668

115625

432426

604451

58668

6834

1025

570

5809

6264

570563

491593

1422373

1505390

1992936

1996983

2603196

2061915

3487440

3433702

41663 37148 224189 200000 224189 200000

1997044

924896

5745821

4600261

5745821

4600261

0.0001

200000000

134100750

1000000

747250

197000

30000000

24000000

30000000

2400

3000

2400

3000

0.0001

1500000000

903263385

579271135

90326

57927

34994471

29813351

-38229897

-32412644

-3142625

-2538346

2603196

2061915

1565313

1958901

269782

2404346

3800

97515

99795

1932610

4466842

-1932610

-4466842

1805

4914

1357341

918487

-668667

-2024203

-913573

-3956813

-5380415

1860440

88269

-5817253

-5468684

-0.01

662161949

572009911

570651636

81000

30000000

57065

3000

28538777

-26943960

1654889

1000000

100

51650

51750

698813

155250

116000

115988

116000

7619499 762 151628 152390 12976 12976

-88269

88269

-5380415

579271135

197000

30000000

57927

3000

29813351

-32412644

-2538346

579271135

197000

30000000

57927

3000

29813351

-32412644

-2538346

21415438 2142 104936 107078 125000 12 613 625 300000 30 10170 10200 35000000 3500 339500 343000 17500000 1750 169750 171500

200000000

20000

2060000

2080000

89881

49651812

-6000000

4965

-600

-4365

435250

435206

435250

115000 11 114989 115000

-1860440

1860440

-3956813

903263385

747250

24000000

90326

2400

34994471

-38229897

-3142625

903263385

747250

24000000

90326

2400

34994471

-38229897

-3142625

-3956813

-5380415

97515

99795

228291

219975

41250

217962

753736

668667 -792757

3800

46551

-58642

38234

1552837

2706799

-486585

-1499434

14041

76905

-14041

-76905

435250

116000

25000

107078

152390

78970

398618

35000 1069972

498358

964744

-2268

-611595

58668

670263

56400

58668

115136

124886

3626325

698812 1860440 88269

1411333

10200 115625 385875

NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc., (“CUBT” or the “Company”), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the Company’s business model. The Company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market. In July 2023 the Company began the process of forming a wholly owned subsidiary - Curative Biotech Japan KK.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates during 2023 and 2022 include valuation of intangible assets, valuation of stock-based compensation and warrant and option issuance valuations and the valuation of deferred tax assets. Actual results could differ from these estimates. (c) Cash and equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents at December 31, 2023 and 2022. (d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are generally amortized over the period of benefit. ( e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Depreciation expense was $456 and $456 for the years ended December 31, 2023 and 2022, respectively. (f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives. These assets are reviewed for impairment when events or circumstances indicate that the carrying amount of the asset may not be recoverable. Intangible assets with indefinite useful lives are amortized using a presumed life of 20 years, and are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount. (j) Revenue Recognition The Company adopted and will follow Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer”. This revenue recognition standard has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. (k) Stock based compensation Stock-based compensation is accounted for based on the requirements of ASC 718 and ASU 2018-07 Compensation - Stock Compensation. ASU 2018-07 simplified the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share-based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting, which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. Share-Based Payment Topic of ASC 718 requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award or the vesting period, whichever is lesser. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For share-based payments to non-employees,” the expense is recognized over the service period of the award. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities. (m) Net income (loss) per share Basic income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. At December 31, 2023, the outstanding <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBSvzIvyNdF4">75,127,744 warrants and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqoBqDODaYDf">58,001,500 options and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesBPreferredStockMember_z6PAGyXzS4Yj">99,633,333 and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesCPreferredStockMember_z6nlysttv54l">387,112,879 shares issuable upon conversion of the Series B and Series C preferred stock, respectively, to common stock are anti-dilutive. At December 31, 2022, the outstanding <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2Hzxah0nxBd">74,027,741 warrants and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zeOp4P8E0pK9">11,082,537 options and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesBPreferredStockMember_zKgY1L27roub">26,266,667 and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesCPreferredStockMember_z8CJcpPeq7Qg">248,259,058 shares issuable upon conversion of the Series B and Series C preferred stock, respectively, to common stock are anti-dilutive. (n) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates during 2023 and 2022 include valuation of intangible assets, valuation of stock-based compensation and warrant and option issuance valuations and the valuation of deferred tax assets. Actual results could differ from these estimates.

(c) Cash and equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents at December 31, 2023 and 2022.

(d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are generally amortized over the period of benefit.

( e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Depreciation expense was $456 and $456 for the years ended December 31, 2023 and 2022, respectively.

456

(f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives. These assets are reviewed for impairment when events or circumstances indicate that the carrying amount of the asset may not be recoverable. Intangible assets with indefinite useful lives are amortized using a presumed life of 20 years, and are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

P20Y

(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(j) Revenue Recognition The Company adopted and will follow Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer”. This revenue recognition standard has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied.

(k) Stock based compensation Stock-based compensation is accounted for based on the requirements of ASC 718 and ASU 2018-07 Compensation - Stock Compensation. ASU 2018-07 simplified the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share-based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting, which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. Share-Based Payment Topic of ASC 718 requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award or the vesting period, whichever is lesser. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For share-based payments to non-employees,” the expense is recognized over the service period of the award. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(m) Net income (loss) per share Basic income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. At December 31, 2023, the outstanding <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBSvzIvyNdF4">75,127,744 warrants and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqoBqDODaYDf">58,001,500 options and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesBPreferredStockMember_z6PAGyXzS4Yj">99,633,333 and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesCPreferredStockMember_z6nlysttv54l">387,112,879 shares issuable upon conversion of the Series B and Series C preferred stock, respectively, to common stock are anti-dilutive. At December 31, 2022, the outstanding <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2Hzxah0nxBd">74,027,741 warrants and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zeOp4P8E0pK9">11,082,537 options and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesBPreferredStockMember_zKgY1L27roub">26,266,667 and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesIssuableUponConversionOfSeriesCPreferredStockMember_z8CJcpPeq7Qg">248,259,058 shares issuable upon conversion of the Series B and Series C preferred stock, respectively, to common stock are anti-dilutive.

75127744

58001500

99633333

387112879

74027741

11082537

26266667

248259058

(n) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $4.0 million and cash used in operations of approximately $0.5 million. The Company also had a working capital deficit and accumulated deficit and deficit in stockholders’ equity of approximately $5.1 million, $38.2 million and $3.1 million at December 31, 2023. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to continue its research and development and related activities.

-4000000.0

-500000

5100000

-38200000

-3100000

NOTE 4 - INTANGIBLE ASSETS During the 4th quarter 2021, the Company acquired the following intangible asset: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">MABT Covid-19 license The Company entered into a licensing agreement with Mid-Atlantic BioTheraputics, Inc., (MABT), to license MABT’s COVID-19 vaccine which is composed of a recombinant S1 and S2 protein from SARS-CoV-2 plus an IMT504 adjuvant. The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zxPuUZ5mw192" title="Common stock issued to acquire license, shares">12,500,000 shares of common stock valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20230101__20231231__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zdZIOb61iZf4" title="Common stock issued to acquire license">1,425,000, ($<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zw42YNtk7dvc" title="Common stock issued to acquire license, per price share">0.11 per share), to acquire this license. The stock price was determined at the closing price on the date the agreement was executed and the obligation to issue arose. In April 2022, the Company paid $<span id="xdx_90F_eus-gaap--LegalFees_c20220401__20220430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zBMYqIbj4Jc2" title="Regulatory and legal costs">39,632 of regulatory and legal costs related to this license. Amortization expense for the years ended December 31, 2023, and 2022 was $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zodLxxRWKPL3" title="Amortization expense">73,282 and $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zEcN7EP4txQ3" title="Amortization expense">72,774, respectively, and a net balance of $<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zqNSdFoLWX85" title="Intangible assets, net">1,270,625 and $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zfnC6IkjQlFf" title="Intangible assets, net">1,341,875 at December 31, 2023 and 2022, respectively.</td></tr></table> Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 4 - INTANGIBLE ASSETS, continued During the 4th quarter 2020, the Company acquired the following intangible assets: (b) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20201201__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zPVVuwpq2c14" title="Issuance of shares for service">22,500, one-half in cash and one-half in common stock of the Company. The Company began amortizing this cost over <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zVxWGdyfoW82" title="Amortization period">3 years once it was operational. Amortization expense for the years ended December 31, 2023, and 2022 was $7,500 and $7,500, respectively, and a net balance of $1,250 and $8,750 at December 31, 2023 and 2022, respectively. (c) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTheraputics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immununotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise $<span id="xdx_90A_ecustom--ProceedsForLicenseDevelopment_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zCCunQ6qrAU2" title="License development">6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A. <span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6MOvGfh2507" title="Research and development arrangement, description">The total cost for this license is <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember_zv2HrcnbMvo2" title="Common shares issued for intangible assets, shares">20 million shares of the Company’s common stock, issuable in three tranches - 1- <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__srt--RangeAxis__srt--MaximumMember_zU2ShC5P1qcf" title="Common shares issued for intangible assets, shares">7 million shares upon execution of the license (which have been issued, valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pid_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zobGMvuiI9Oi" title="Common shares issued for intangible assets, value">91,000), 2- <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__srt--RangeAxis__srt--MaximumMember_zFXpeAVyLnXf" title="Common shares issued for intangible assets, shares">6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__srt--RangeAxis__srt--MaximumMember_zQXQZWnTRXoi" title="Common shares issued for intangible assets, shares">6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504. In March 2022, the Company paid $<span id="xdx_905_eus-gaap--LegalFees_c20220301__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_z41Zl9eo8UQ3" title="Regulatory and legal costs">30,666 of regulatory and legal costs related to this license. Amortization expense for the years ended December 31, 2023, and 2022 was $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zfvWgYwQtAW3" title="Amortization expense">6,200 and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zmWIQ5mEFnwd" title="Amortization expense">5,925, respectively, and a net balance of $<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_z8jdpbgFYhCd" title="Intangible assets, net">104,232 and $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_z975QhFjhLae" title="Intangible assets, net">110,432 at December 31, 2023 and 2022, respectively. (d) National Institute of Health (NIH) Patent license #1 In October 2020, the Company entered into an exclusive 24-month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016, and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of gioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties. This license calls for the payment of a non-creditable non-refundable license issue royalty of $<span id="xdx_907_eus-gaap--RoyaltyExpense_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zj7LEEDZMJra" title="Royalty expense">10,000, paid at issuance and $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zkBo9Tc897l1" title="Payments of issuance costs">5,000 on the one-year anniversary, for a total value of $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zTVIqwYaw5F2" title="Payment of non-refundable license issue royalty">15,000.. In October 2023, the NIH agreed to extend this agreement for an additional 12 months. Amortization expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zEocEZogs7Fd" title="Amortization expense">0 and $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zYQpOwpALLV7" title="Amortization expense">7,738, respectively, and a net balance of $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zwVDSdPhhEe7" title="Intangible assets, net::XDX::-">0 and $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_dxL_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_zgcK1y5wGfq" title="Intangible assets, net::XDX::-">0 at December 31, 2023 and 2022, respectively. (e) National Institute of Health (NIH) Patent license #2 In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases. This license requires two separate royalty streams of payments: First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary. Amortization expense for the years ended December 31, 2023 and 2022 was $8,674 and $5,403, respectively, and a net balance of $1,756 and $6,225 at December 31, 2023 and 2022, respectively. Second is an ongoing royalty schedule: an initial royalty of $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_zvC9AcQVITAk" title="Patent expense initial amount payable">5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. <span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsIntentOrAbilityToRenewOrExtendArrangement_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_zIYtNf26mSG6" title="Option extension description">The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_zxQVtr53OAB6" title="Payment of non-refundable license issue royalty">45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty. See footnote 20 for extension of the third anniversary payment. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 4 - INTANGIBLE ASSETS, continued The Company’s intangible assets, net of accumulated amortization, consists of the following at December 31,: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 87%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated life (years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_z02TFtHvOkzb" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zaRDgO7kDbf2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_z8COi2KPAORa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Website</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zBysSzWEiIAk" title="Estimated life (years)">3</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zbwueapKM8Pa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">MABT Covid-19 license</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zYRjUySOkinl" title="Estimated life (years)">20</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,306,701</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,379,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8bBtOaexoTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">IMT504 Patent license</td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmuYHJ39JBTk" title="Estimated life (years)">20</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,432</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_z9PvNJbkkzjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NIH Patent license #1</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_z3ZkpxWWBqte" title="Estimated life (years)">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember_zG7OVPAiMtWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NIH Patent license #2</td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember_zUTyfrpp06Za" title="Estimated life (years)">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,225</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zxryAWQQV193" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zRcrkzbDVJYa" title="Estimated life (years)">20</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,434</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zSagDRnWH7U5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,422,373</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,505,390</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accumulated amortization was $208,323 and $118,768 at December 31, 2023 and 2022, respectively

12500000

1425000

0.11

39632

73282

72774

1270625

1341875

22500

P3Y

7500

1250

8750

6500000

The total cost for this license is 20 million shares of the Company’s common stock, issuable in three tranches

20000000

7000000

91000

6500000

30666

6200

5925

104232

110432

10000

5000

15000

7738

8500

8674

5403

1756

6225

5000

The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty. See footnote 20 for extension of the third anniversary payment

45000

The Company’s intangible assets, net of accumulated amortization, consists of the following at December 31,: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 87%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated life (years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_z02TFtHvOkzb" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zaRDgO7kDbf2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_z8COi2KPAORa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Website</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zBysSzWEiIAk" title="Estimated life (years)">3</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zbwueapKM8Pa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">MABT Covid-19 license</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MABTCovidNineteenLicenseMember_zYRjUySOkinl" title="Estimated life (years)">20</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,306,701</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,379,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8bBtOaexoTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">IMT504 Patent license</td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmuYHJ39JBTk" title="Estimated life (years)">20</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,432</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_z9PvNJbkkzjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NIH Patent license #1</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_z3ZkpxWWBqte" title="Estimated life (years)">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember_zG7OVPAiMtWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NIH Patent license #2</td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember_zUTyfrpp06Za" title="Estimated life (years)">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,225</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zxryAWQQV193" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_pp0p0_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zRcrkzbDVJYa" title="Estimated life (years)">20</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,434</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zSagDRnWH7U5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,422,373</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,505,390</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P3Y

1250

8750

P20Y

1306701

1379983

P20Y

104232

110432

P2Y

P3Y

1756

6225

P20Y

8434

1422373

1505390

208323

118768

NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arm’s length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arm’s length transaction. During the second quarter of 2023, a related party owned by two officers of the Company extended a loan of $15,000, which carries an 8% rate of interest and matures on September 2, 2023. In September the maturity date was extended to December 15, 2023. In December 2023, the maturity was extended to February 15, 2024. At December 31, 2023, the balance was $15,868, on the accompanying balance sheet, including accrued interest of $868. See footnote 20 for extension to May 15, 2024. During the first quarter of 2023, a related party owned by two officers of the Company, extended a loan of $20,000, which carries an 8% rate of interest and matured on June 14, 2023. In June 2023, the maturity of this note was extended to September 14, 2023. In September the maturity date was extended to December 15, 2023. In December 2023, the maturity was extended to February 15, 2024. At December 31, 2023, the balance was $21,280, on the accompanying balance sheet, including accrued interest of $1,280. See footnote 20 for extension to May 15, 2024.

15000

0.08

2023-09-02

In September the maturity date was extended to December 15, 2023. In December 2023, the maturity was extended to February 15, 2024.

15868

868

20000

0.08

2023-06-14

In June 2023, the maturity of this note was extended to September 14, 2023. In September the maturity date was extended to December 15, 2023. In December 2023, the maturity was extended to February 15, 2024.

21280

1280

NOTE 6 - NOTES PAYABLE On May 27, 2022, the Company issued a promissory note in exchange for $200,000 in cash. This note carries a 12% interest rate, interest payable monthly, and a six-month maturity. At maturity, the maturity was extended for an additional six months. On May 27, 2023, the maturity date was extended to December 16, 2023, and the interest rate was increased to 18%, interest payable monthly. On December 16, 2023, the maturity date was extended to January 31, 2024, upon the payment of $18,000 of accrued interest. In January 2024, the note was extended to May 31, 2024, upon the payment of a $6,000 late fee by February 1, 2024, and $6,250 for accrued interest and a $250 late fee by February 29, 2024. Upon default, as defined in the note, all amounts become due. The balance was $224,189 including principal of $200,000 and accrued interest of $18,189 and a late fee of $6,000 and $200,000, on the accompanying balance sheet at December 31, 2023 and 2022, respectively. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022

200000

This note carries a 12% interest rate, interest payable monthly, and a six-month maturity

the maturity date was extended to December 16, 2023

0.18

the maturity date was extended to January 31, 2024

18000

In January 2024, the note was extended to May 31, 2024

6000

6250

250

224189

200000

18189

6000

200000

NOTE 7 - SENIOR SECURED NOTE PAYABLE On March 2, 2022, the Company issued a 12-month Senior Secured Note with a face amount of $1,142,857, with a stated <span id="xdx_902_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_pid_dp_uPure_c20220302__20220302__us-gaap--DebtInstrumentAxis__custom--TwelveMonthSeniorSecuredNoteMember_zZTUoiwHNXP7" title="Debt instrument original interest rate">12.5% original issue discount (OID). The Note carries a <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220302__us-gaap--DebtInstrumentAxis__custom--TwelveMonthSeniorSecuredNoteMember_zFzOiDMDuSW9" title="Debt interest rate">12.5% interest rate with interest-only payable monthly from April through August 2022. The Company received $869,972 in cash, net of the OID of $142,857 and legal and other fees in the amount of $120,028. The Note is secured by all the tangible and intangible assets of the Company and is summarized as follows: SUMMARY OF NOTES SECURED BY TANGIBLE AND INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zFD2Tg7iuo99" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zN3vnAnfz0q9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayable_iI_maSTBLAzYBj_zlTAn7obrrWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,142,857</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,142,857</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedInterestAndPenalties_iI_maSTBLAzYBj_zTtl5voZQq0l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued interest and penalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msSTBLAzYBj_zhp9z2yuaSXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unamortized discounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(217,961</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBankLoansAndNotesPayable_iTI_mtSTBLAzYBj_zdADbQDuDWR6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Senior secured short term note payable and accrued interest, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,997,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">924,896</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Beginning in September 2022, the Company was required to make monthly redemptions at the rate of 110% of one seventh of the original principal amount, ($179,592), plus interest. It also carries a mandatory prepayment at 125% of the original principal amount, or $1,428,571, less any redemptions made, plus any unpaid accrued interest upon the completion of a Qualified Offering, as defined or sale of substantially all assets of the Company or a change of control of the Company. In the event that the Company issue or sells additional shares of Common Stock or Common Stock Equivalents in a Qualified Offering at a price per share which multiplied by 75% is less than the Warrant Calculation Price, the number of Warrant Shares issuable upon exercise of this Warrant will increase to be equal to the product obtained by multiplying: (WCP/BP) x (WS) whereby: (WCP) = the Warrant Calculation Price. (BP) = 75% of the price per share sold in the Qualified Offering. (WS) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant immediately prior to the Qualified Offering if such exercise were by means of a cash exercise rather than a cashless exercise; The term “Warrant Calculation Price” means $0.05 The Note is convertible at the election of the holder into common stock of the Company upon an event of default, as defined. The conversion price is <span id="xdx_904_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20220101__20220930__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zN9KbqYExDni" title="Debt conversion price percentage">70% of the lowest closing price of the Company’s common stock for the prior <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20220101__20220930__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zrQRGVrqtLr" title="Trading days">20 trading days. The lender received five-year warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220930__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zH1MvBb8nxr" title="Warrants to purchase shares">22,857,143 shares of common stock of the Company, with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220930__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zEQ2BwHCNMQb" title="Exercise price">0.0001 per share. The relative fair value of these warrants were recorded as debt discount in the amount of $531,983 which is being amortized over the term of the Note. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022. In August 2022, the Company and the lender agreed to the first modification of the Note. In exchange for a one-month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from $10 million to $7.2 million; modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received 1,904,762 additional warrants having a fair value of $58,884, ($<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleLiquidationPreferencePerShare_iI_pid_uUSDPShares_c20220831__us-gaap--DebtInstrumentAxis__custom--FirstModificationMember_z4ga1oM14Boe" title="Debt discount per share">0.03 per share), which were recorded as an additional debt discount and amortized over the remaining life of the Note. In October 2022, the Company and the lender agreed to the second modification of the Note. The first payment due was delayed from October 2, 2022, to October 17, 2022. In October 2022, the Company and the lender agreed to the third modification of the Note. The first payment due was delayed from October 17, 2022, to November 2, 2022. The lender received <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221031__us-gaap--DebtInstrumentAxis__custom--ThirdModificationMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember_z6DGQFlqi91c" title="Purchase of common stock warrants">1,904,762 additional warrants having a fair value of $36,053, which were recorded as an additional debt discount and amortized over the remaining life of the Note. In November 2022, the Company and the lender agreed to the fourth modification of the Note. The first payment due was delayed from November 2, 2022, to November 17, 2022. In November 2022, the Company and the lender agreed to the fifth modification of the Note. The first payment due was delayed from November 17, 2022, to December 17, 2022. The lender received <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--FifthModificationMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember_zJOFcAjoywT7" title="Purchase of common stock warrants">1,904,762 additional warrants having a fair value of $37,955, which were recorded as an additional debt discount and amortized over the remaining life of the Note. In December 2022, the Company and the lender agreed to the sixth modification of the Note. The first payment due was delayed from December 17, 2022, to January 17, 2023. The lender received <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--SixthModificationMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember_zC9Q0UvWfMH3" title="Purchase of common stock warrants">1,904,762 additional warrants having a fair value of $33,936, which were recorded as an additional debt discount and amortized over the remaining life of the Note. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 7 - SENIOR SECURED NOTE PAYABLE, continued In the first quarter 2023, the Company and the lender agreed to the seventh through eleventh modifications of the Note. The maturity was reset to May 16, 2023; the default and optional redemption rates were reset to 137.5% and the qualified offering, as described, was reset to $3 million. As part of these amendments the Company paid a total of $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pid_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeventhThroughEleventhModificationMember_zSuagFapssIj" title="Accrued interest">36,600 of accrued interest. In the second quarter 2023, the Company and the lender agreed to the twelfth modification of the Note. The maturity was reset to July 2, 2023; the default and optional redemption rates were reset to <span id="xdx_904_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20230401__20230630__us-gaap--DebtInstrumentAxis__custom--TwelfthModificationMember_ziSucfRD69K2" title="Debt instrument redemption percentage">142.5% and the qualified offering, as described, was reset to $3 million in one continuous offering of a single security. In the third quarter 2023, the Company and the lender agreed to the 13th modification of the Note. In exchange for the right to convert to common stock at 1.5 times the original principal balance should there be an event of default, the lender agreed to a five-month extension of the maturity of this Note to December 2, 2023, and accrual of the monthly interest from July 2, 2023, to be paid at maturity. In the fourth quarter 2023, the Company and the lender agreed to the 14th and 15th modifications of the Note. In exchange for receipt of $5,000 of accrued interest for each modification, the maturity date was extended to January 31, 2024. Interest expense in 2023 and 2022 was $142,860 and $107,145 and there was $61,430 and zero accrued which is included in the aggregate balance of $1,997,044 and $924,896 respectively at December 31, 2023 and 2022. Subsequent to December 31, 2023, certain terms of the note were amended for the 16th time and was extended the note to April 2, 2024. (See Note 20) All penalties and interest were recorded as interest expense with penalties of $792,757and interest of $142,860 in 2023 and interest expense of $107,145 in 2022. Amortization of the discounts was $217,961 and $44,924 in 2023 and 2022, respectively.

1142857

0.125

869972

142857

120028

The Note is secured by all the tangible and intangible assets of the Company and is summarized as follows: SUMMARY OF NOTES SECURED BY TANGIBLE AND INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zFD2Tg7iuo99" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zN3vnAnfz0q9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayable_iI_maSTBLAzYBj_zlTAn7obrrWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,142,857</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,142,857</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedInterestAndPenalties_iI_maSTBLAzYBj_zTtl5voZQq0l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued interest and penalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msSTBLAzYBj_zhp9z2yuaSXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unamortized discounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(217,961</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBankLoansAndNotesPayable_iTI_mtSTBLAzYBj_zdADbQDuDWR6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Senior secured short term note payable and accrued interest, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,997,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">924,896</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1142857

854187

217961

1997044

924896

1.10

179592

1.25

1428571

In the event that the Company issue or sells additional shares of Common Stock or Common Stock Equivalents in a Qualified Offering at a price per share which multiplied by 75% is less than the Warrant Calculation Price, the number of Warrant Shares issuable upon exercise of this Warrant will increase to be equal to the product obtained by multiplying: (WCP/BP) x (WS) whereby: (WCP) = the Warrant Calculation Price. (BP) = 75% of the price per share sold in the Qualified Offering. (WS) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant immediately prior to the Qualified Offering if such exercise were by means of a cash exercise rather than a cashless exercise; The term “Warrant Calculation Price” means $0.05

0.70

22857143

0.0001

531983

10000000

7200000

the payment schedule from seven (7) months to six (6) months

1904762

58884

0.03

The first payment due was delayed from October 2, 2022, to October 17, 2022

The first payment due was delayed from October 17, 2022, to November 2, 2022

1904762

36053

The first payment due was delayed from November 2, 2022, to November 17, 2022

The first payment due was delayed from November 17, 2022, to December 17, 2022

1904762

37955

The first payment due was delayed from December 17, 2022, to January 17, 2023

1904762

33936

2023-05-16

1.375

3000000

36600

2023-07-02

1.425

3000000

2023-12-02

5000

2024-01-31

142860

107145

61430 0

1997044

924896

792757

142860

107145

217961

44924

NOTE 8 - LIABILITY TO ISSUE COMMON STOCK During the 4th quarter 2023, the Company issued 300,000 shares of common stock valued at $10,200, or $0.034 per share and cancelled the 375,000 shares to be issued under an agreement and previously accrued and valued at $46,306 to a consultant by mutual consent. A gain of $41,250 on this cancellation was recorded in general and administrative expense.

300000

10200

0.034

375000

46306

41250

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY At December 31, 2023 and 2022, the Company has 1,500,000,000 shares of par value $0.0001 common stock authorized and 903,263,385 and 579,271,135 issued and outstanding, respectively. At December 31, 2023 and 2022, the Company has 200,000,000 shares of $0.0001 par value preferred stock authorized and 747,250 and 197,000 Series B issued and outstanding, respectively. Preferred Stock The preferred shares have the following respective rights and privileges: <span id="xdx_90A_eus-gaap--PreferredStockVotingRights_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzmc5K33dVwl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating <span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfgcsRYy0pXi">35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable at the Company’s option for the greater of 45% of the total market value of the common shares or the calculation of the book value of the Company made by an independent audit firm or $5,000,000. There are no dividend rights and no stated liquidation value. Series B Preferred are convertible in common shares of common stock at a conversion price of $0.0075 per share based on the purchase price of the preferred shares; are redeemable at the Company’s option at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation. There are no dividend rights and a stated liquidation value of $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXE2OIZzxh64" title="Preferred stock, liquidation preference per share">1.00 per share outstanding. The Series B shares may be subject to mandatory conversion based on a fundamental change, as defined. Series C Preferred are convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carries ten votes for each common share that the Series C is convertible into at the record date. There are no dividend rights and have liquidation rights commensurate with the underlying common stock each share of Series C is convertible into. The Series C shares may be subject to mandatory conversion based on a fundamental change, as defined. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the fourth quarter 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zzAnFFvliKp5" title="Number of shares, services">176,500 shares of Series B preferred stock in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zijXH3WqoVq4" title="Number of value, services">61,500 in cash and $<span id="xdx_903_eus-gaap--PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOtK9ameMVa5" title="Subscription receivable">115,000 subscription receivable. During the third quarter 2023, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zZaGBYMupZy7" title="Number of shares, services">210,000 shares of Series B preferred stock in exchange for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zAy5rUgM9iu1" title="Number of value, services">210,000 in cash. During the first quarter 2023, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zkMVKkPR67sc" title="Number of shares, services">163,750 shares of Series B preferred stock in exchange for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zBsDcaxsjXGi" title="Number of value, services">163,750 in cash. During the fourth quarter 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zKrT2C5sElX8" title="Number of shares, services">116,000 shares of Series B preferred stock in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_z13Kuuf5RbV2" title="Number of value, services">116,000 in cash. A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was $1,860,440 and $88,269 for the years ended December 31, 2023 and 2022, respectively. Common Stock During the fourth quarter 2023, the Company increased its authorized common shares to 1,500,000,000. During the fourth quarter 2023, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zFkeAiON5m2g" title="Number of issuance of shares">35,000,000 shares of common stock valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zUs5SleTT9W2" title="Number of issuance, value">343,000 to an officer of the company as an inducement to enter into a new 24-month employment agreement. The value of these shares will be amortized to expense over their six-month vesting period. Also, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FormerOfficerMember_zhIwlcyEAQ9c" title="Number of issuance of shares">15,000,000 shares of common stock valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FormerOfficerMember_zMnHQQB1PXXg" title="Number of issuance, value">147,000 to a now former officer and director of the Company as an inducement to resign from the Board of Directors. These shares carry a 24-month non-compete clause. The value of these shares will be amortized over the life of the non-compete clause. In addition, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zvXUk7ZyNMk3" title="Number of issuance of shares">2,500,000 shares of common stock valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zjUJCTiSTEI8" title="Number of issuance, value">24,500 to a now former director of the Company as an inducement to resign from the Board of Directors. These shares carry a 24-month non-compete clause. The value of these shares will be amortized over the life of the non-compete clause. The total value of these 52,500,000 shares was $514,500 of which $128,675 was amortized to expense in 2023 with $385,875 remaining in prepaid expense at December 31, 2023. During the fourth quarter 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoCurrentOfficerMember_zLAz46MKiwul" title="Number of issuance of shares">200,000,000 shares of common stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoCurrentOfficerMember_zpNbfseKLici" title="Number of issuance, value">2,080,000 to two current and one former officer of the company as settlement of $1,411,333 accrued and unpaid salary. The Company recognized a loss on debt extinguishment of $668,667 on this settlement. During the fourth quarter 2023, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z5aMxH3UyeT5" title="Number of issuance of shares">300,000 shares of common stock valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zonBYWA7545e" title="Number of issuance, value">10,200 to a consultant to settle the accumulated liability to issue common shares. During the fourth quarter 2023, investors exercised 21,540,438 warrants for cash of $107,078 and a subscription receivable of $<span id="xdx_900_eus-gaap--PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsgNGj5fKBJh" title="Subscription receivable">625 under an inducement offer which reduced the exercise price from $0.09, $0.11 and $0.15 per share to $0.005 per share. Upon exercise the Company issued 21,540,438 common shares and 21,540,438 replacement warrants with an exercise price of $0.02. Since the value of the inducement is considered an offering cost under ASU 2021-04 the value of the inducement offer including the replacement warrants was limited to the $107,078 cash proceeds and did not have an impact on the financial statements as the fair value of the modified and replacement warrants would be considered equity issuance cost which would be credited and charged to additional paid in capital resulting in no net effect. During the first quarter 2023, the Company issued 49,651,812 shares of common stock to one employee for the conversion of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStockDeemedDividendMember_zqzAvWnywP5l" title="Number of issuance of shares">6,000,000 shares of Series C preferred stock, valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStockDeemedDividendMember_zUd4XZroY4yh" title="Number of issuance, value">3,626,365, based on the then accumulated deemed dividend. During the fourth quarter 2022, investors exercised 7,619,499 warrants for cash of $152,390 under an inducement offer which reduced the exercise price from $0.09, $0.11 and $0.15 per share to $0.02 per share. Upon exercise the Company issued 7,619,499 common shares and 7,619,499 replacement warrants with an exercise price of $0.02.Since the value of the inducement is considered an offering cost under ASU 2021-04 the value of the inducement offer including the replacement warrants was limited to the $152,390 cash proceeds and did not have an impact on the financial statements as the fair value of the modified and replacement warrants would be considered equity issuance cost which would be credited and charged to additional paid in capital resulting in no net effect. During the first quarter 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220331__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zATvyfiiDV7h" title="Common shares issued for services, shares">1,000,000 shares of common stock to one employee for past services valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220331__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJM9owTlL1nj" title="Common shares issued for services">51,750, based on the closing price of the stock on grant date. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022

1500000000

0.0001

903263385

579271135

200000000

0.0001

747250

197000

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date

0.35

0.45

5000000

0.0075

1.25

1.00

0.30

176500

61500

115000

210000

163750

116000

1860440 88269

1500000000

35000000

343000

15000000

147000

2500000

24500

52500000

514500

128675

385875

200000000

2080000

1411333

668667

300000

10200

During the fourth quarter 2023, investors exercised 21,540,438 warrants for cash of $107,078 and a subscription receivable of $625 under an inducement offer which reduced the exercise price from $0.09, $0.11 and $0.15 per share to $0.005 per share. Upon exercise the Company issued 21,540,438 common shares and 21,540,438 replacement warrants with an exercise price of $0.02. 21540438

107078

625

107078

49651812

6000000

3626365

During the fourth quarter 2022, investors exercised 7,619,499 warrants for cash of $152,390 under an inducement offer which reduced the exercise price from $0.09, $0.11 and $0.15 per share to $0.02 per share. Upon exercise the Company issued 7,619,499 common shares and 7,619,499 replacement warrants with an exercise price of $0.02. 7619499

152390

1000000

51750

NOTE 10 – WARRANTS SCHEDULE OF WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: left">Beginning balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zybteBnORXli" style="width: 16%; text-align: right" title="Warrants, Begining balance">75,527,744</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPspn4XLgLX6" style="width: 16%; text-align: right" title="Warrants, Begining balance">45,551,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8tVIDNWhC73" style="text-align: right" title="Warrants, Issued">21,540,438</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3xEK974KxI5" style="text-align: right" title="Warrants, Issued">38,095,694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9WVfuQsRa08" style="text-align: right" title="Warrants, Exercised">(21,540,438</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOpfy1dnOJs5" style="text-align: right" title="Warrants, Exercised">(7,619,499</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Expired/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUpswGUEJI8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Cancelled">(400,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE7yjxfRLddj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Cancelled">(500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdD8rvsJuJe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Ending balance">75,127,744</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zojyC9XDnLdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Ending balance">75,527,744</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrants outstanding at December 31, 2023: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 1in"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_z1JyBT6vmAXf" style="width: 30%; text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right">48 months</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zCCwTS3MLS9k" style="width: 30%; font-weight: bold; text-align: right" title="Warrants exercise price">0.0001</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_zGHqc3z4qSXb" style="text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_zMNEqhUghLq4" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zVHkP5y13XJ" style="font-weight: bold; text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zGwsBmYMHER8" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_z9wBjEELiJZc" style="font-weight: bold; text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44 months </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_zDhOV0IvGpN" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zxPeVg5YKsy7" style="text-align: right" title="Number of warrants outstanding">22,857,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_z62VLq9UzsAa" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFiveMember_z6ROByot94Xd" style="text-align: right" title="Number of warrants outstanding">21,540,438</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFiveMember_zP04CToqnZU8" style="text-align: right" title="Warrants exercise price">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSixMember_zrwlRCiJ6uL6" style="text-align: right" title="Number of warrants outstanding">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSixMember_zdjuNWfBfZNb" style="text-align: right" title="Warrants exercise price">0.09</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSevenMember_zA6dLG1HBXL6" style="text-align: right" title="Number of warrants outstanding">4,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSevenMember_zOVTnqm4lJxa" style="text-align: right" title="Warrants exercise price">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceEightMember_zvmJ4yYV4FF9" style="text-align: right" title="Number of warrants outstanding">3,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceEightMember_zz6y3UE5Kdt4" style="text-align: right" title="Warrants exercise price">0.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceNineMember_zBe9IOtriLF3" style="text-align: right" title="Number of warrants outstanding">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceNineMember_z5FCqRxSGde6" style="text-align: right" title="Warrants exercise price">0.124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTenMember_zpERKAYsKMKe" style="text-align: right" title="Number of warrants outstanding">1,111,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTenMember_zGKpd2U5ZtP1" style="text-align: right" title="Warrants exercise price">0.14</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceElevenMember_zMOs4mIRWDS3" style="text-align: right" title="Number of warrants outstanding">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceElevenMember_zS36xjPY8gW9" title="Warrants outstanding, remaining life">12 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceElevenMember_zp5cEDIkUrjd" style="text-align: right" title="Warrants exercise price">0.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwelveMember_zx2FwFbEGIcb" style="text-align: right" title="Number of warrants outstanding">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwelveMember_z4ju5VP5r3dh" title="Warrants outstanding, remaining life">8 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwelveMember_zWdWkxhXXeoc" style="text-align: right" title="Warrants exercise price">0.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThirteenMember_ztgGv9i201ff" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding">5,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThirteenMember_zyQQCVbn65N7" title="Warrants outstanding, remaining life">8 months</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThirteenMember_z8wolJDORU1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercise price">0.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">75,127,744</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">31.6 weighted average</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">$0.048 weighted average</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> The aggregate intrinsic value of vested share options (the market value was less the exercise price) at December 31, 2023 was zero. At December 31, 2023 and 2022, there were 75,127,744 and 75,527,744 warrants fully vested issued and outstanding with a weighted average exercise price of $0.048 and $0.0659 per share. During the fourth quarter 2023, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHikEGOLjX2" title="Replacement warrants for purchase of common stock">21,540,438 replacement warrants for the purchase of common stock with an exercise price of $0.02 per share in conjunction with the exercise of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvbe6cedMN08" title="Replacement warrants for purchase of common stock">21,540,438 warrants for $107,078 in cash and a subscription receivable of $<span id="xdx_909_eus-gaap--PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBX8DfB3TXk5" title="Subscription receivable">625, ($<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKuFkeD8YY" title="Weighted average exercise price">0.005 per share) under an inducement offer. There was no net accounting effect of this issuance. (See common stock above) Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 10 - WARRANTS, continued During the fourth quarter 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDDE8cpvmW93" title="Replacement warrants for purchase of common stock">7,619,499 replacement warrants for the purchase of common stock with an exercise price of $0.02 per share in conjunction with the exercise of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhFRafvPYAr" title="Replacement warrants for purchase of common stock">7,619,499 warrants for $152,390, ($<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFiveMember_zXlIP9DjXYT2" title="Weighted average exercise price">0.02 per share) under an inducement offer. There was no net accounting effect of this issuance. (See common stock above) During the fourth quarter 2022, The Company and the lender agreed to five modifications of the Note. In exchange for ultimately a three and a half-month extension of the first payment date, the lender received 1,904,762 additional warrants three times having a fair value of $36,054, $37,955 and $33,936, ($0.019; $0.02 and $0.018 per share, respectively), which was recorded as an additional debt discount and amortized over the remaining life of the Note. During the third quarter 2022, The Company and the lender agreed to a modification of the Note. In exchange for a one-month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from $10 million to $7.2 million; modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received 1,904,762 additional warrants having a fair value of $58,884, ($0.03 per share), which was recorded as an additional debt discount and amortized over the remaining life of the Note. On March 2, 2022, the Company issued to a lender warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220302__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_zcmKSN7FgkU2" title="Warrants to purchase common stock">22,857,147 shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220302__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_z2COdyu1Lf7b" title="Weighted average exercise price">0.0001 per share in conjunction with the issuance of the debt. The warrants were valued at the relative fair value of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pid_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_zTAZ7QlQClK9" title="Debt discount">531,983 based on a fair value of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pid_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_zNHTbkNTbg5a" title="Fair value of warrants">1,369,303 calculated using the Black-Scholes pricing model. The aggregate value for the initial and extension warrants was $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_pid_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_zOrfYlMBEDxf" title="Warrants issued in connection with debt">698,813. The method utilized to value the warrants granted for services in 2022, was the Black-Scholes pricing model with the following assumption ranges: Expected life - three or five years; stock price between $0.0179 and $0.031; volatility between <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z0o0EYV3jwlh">288% and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zOvdgr6cKGak">313.0%; exercise price between $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220302__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zgobUdOcECwl">0.02 and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220302__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zxs2OI48gfZi">0.0001 and bond equivalent yield rate between <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zyYzZldcipda">1.62% and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220301__20220302__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zV1alNhyIZ1a">5.05%. SCHEDULE OF WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: left">Beginning balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zybteBnORXli" style="width: 16%; text-align: right" title="Warrants, Begining balance">75,527,744</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPspn4XLgLX6" style="width: 16%; text-align: right" title="Warrants, Begining balance">45,551,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8tVIDNWhC73" style="text-align: right" title="Warrants, Issued">21,540,438</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3xEK974KxI5" style="text-align: right" title="Warrants, Issued">38,095,694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9WVfuQsRa08" style="text-align: right" title="Warrants, Exercised">(21,540,438</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOpfy1dnOJs5" style="text-align: right" title="Warrants, Exercised">(7,619,499</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Expired/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUpswGUEJI8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Cancelled">(400,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE7yjxfRLddj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Cancelled">(500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdD8rvsJuJe2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Ending balance">75,127,744</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zojyC9XDnLdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Ending balance">75,527,744</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

75527744

45551549

21540438

38095694

21540438

7619499

400000

500000

75127744

75527744

Warrants outstanding at December 31, 2023: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 1in"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_z1JyBT6vmAXf" style="width: 30%; text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right">48 months</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zCCwTS3MLS9k" style="width: 30%; font-weight: bold; text-align: right" title="Warrants exercise price">0.0001</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_zGHqc3z4qSXb" style="text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_zMNEqhUghLq4" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zVHkP5y13XJ" style="font-weight: bold; text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_zGwsBmYMHER8" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_z9wBjEELiJZc" style="font-weight: bold; text-align: right" title="Number of warrants outstanding">1,904,762</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44 months </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_zDhOV0IvGpN" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zxPeVg5YKsy7" style="text-align: right" title="Number of warrants outstanding">22,857,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_z62VLq9UzsAa" style="text-align: right" title="Warrants exercise price">0.0001</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFiveMember_z6ROByot94Xd" style="text-align: right" title="Number of warrants outstanding">21,540,438</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFiveMember_zP04CToqnZU8" style="text-align: right" title="Warrants exercise price">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSixMember_zrwlRCiJ6uL6" style="text-align: right" title="Number of warrants outstanding">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSixMember_zdjuNWfBfZNb" style="text-align: right" title="Warrants exercise price">0.09</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSevenMember_zA6dLG1HBXL6" style="text-align: right" title="Number of warrants outstanding">4,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceSevenMember_zOVTnqm4lJxa" style="text-align: right" title="Warrants exercise price">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceEightMember_zvmJ4yYV4FF9" style="text-align: right" title="Number of warrants outstanding">3,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceEightMember_zz6y3UE5Kdt4" style="text-align: right" title="Warrants exercise price">0.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceNineMember_zBe9IOtriLF3" style="text-align: right" title="Number of warrants outstanding">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceNineMember_z5FCqRxSGde6" style="text-align: right" title="Warrants exercise price">0.124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTenMember_zpERKAYsKMKe" style="text-align: right" title="Number of warrants outstanding">1,111,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTenMember_zGKpd2U5ZtP1" style="text-align: right" title="Warrants exercise price">0.14</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceElevenMember_zMOs4mIRWDS3" style="text-align: right" title="Number of warrants outstanding">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceElevenMember_zS36xjPY8gW9" title="Warrants outstanding, remaining life">12 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceElevenMember_zp5cEDIkUrjd" style="text-align: right" title="Warrants exercise price">0.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwelveMember_zx2FwFbEGIcb" style="text-align: right" title="Number of warrants outstanding">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwelveMember_z4ju5VP5r3dh" title="Warrants outstanding, remaining life">8 months</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwelveMember_zWdWkxhXXeoc" style="text-align: right" title="Warrants exercise price">0.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThirteenMember_ztgGv9i201ff" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding">5,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThirteenMember_zyQQCVbn65N7" title="Warrants outstanding, remaining life">8 months</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThirteenMember_z8wolJDORU1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercise price">0.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">75,127,744</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">31.6 weighted average</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">$0.048 weighted average</td><td style="font-weight: bold; text-align: left"> </td></tr> </table>

1904762

P48M

0.0001

1904762

P47M

0.0001

1904762

P46M

0.0001

1904762

P44M

0.0001

22857147

P40M

0.0001

21540438

P35M

0.02

3000000

P12M

0.09

4000000

P29M

0.10

3500000

P29M

0.11

500000

P7M

0.124

1111111

P8M

0.14

3000000

P12M

0.15

3000000

P8M

0.15

5000000

P8M

0.20

75127744

P31M18D

0.048

75127744

75527744

0.048

0.0659

21540438

0.02

21540438

107078

625

0.005

7619499

0.02

7619499

152390

0.02

In exchange for ultimately a three and a half-month extension of the first payment date, the lender received 1,904,762 additional warrants three times having a fair value of $36,054, $37,955 and $33,936, ($0.019; $0.02 and $0.018 per share, respectively), which was recorded as an additional debt discount and amortized over the remaining life of the Note. In exchange for a one-month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from $10 million to $7.2 million; modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received 1,904,762 additional warrants having a fair value of $58,884, ($0.03 per share), which was recorded as an additional debt discount and amortized over the remaining life of the Note.

22857147

0.0001

531983

1369303

698813

0.0179

0.031

2.88

3.130

0.02

0.0001

0.0162

0.0505

NOTE 11 - NON-EQUITY INCENTIVE PLAN OPTIONS During the fourth quarter 2023, the Company issued 55,000,000 options to three (one new) members of the Board of Directors. These options carry an exercise price of $0.0001 per share and expire in October 2033. These options were valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20231001__20231231__srt--TitleOfIndividualAxis__custom--BoardOfAdvisoryMember_zxpfJI2dcp1k" title="Number of option issued, value">539,000, ($0.01 per share), and vest at the rate of 25% per quarter beginning January 2nd, 2024. The method utilized to value the options was the Black-Scholes pricing model with the following assumption ranges: Expected life - 6.5 years using the simplified method; stock price $0.0098; volatility 311.4%; exercise price $0.0001 and discount rate 2.52%. In 2023, $89,883 of compensation expense was recognized with $449,117 to be recognized in future periods. At December 31, 2023, the weighted average exercise price is $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20231231_zmrQLJdnE5Bi" title="Weighted average exercise price">0.0001 and the weighted average life is <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231_zi68vp4iPA29" title="Weighted average term">9.83 years. In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1% of the fully diluted issued and outstanding shares upon exercise. These options amounted to 8,081,037 shares at issuance date. These options contain a single recalculation upon the completion of a reverse split of the existing common stock and the Company raising a minimum of $5 million in an offering. These options carry an exercise price of $0.11 per share and expire in September 2031. These options were valued at $436,908 at issuance, ($0.05 per share), and vest 50% upon issuance and <span id="xdx_90E_ecustom--OptionsVestedPercentage_pid_dp_c20220901__20220930__srt--TitleOfIndividualAxis__custom--BoardOfAdvisoryMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKwXXKMyc8e1">50% in September 2022. The method utilized to value the options was the Black-Scholes pricing model with the following assumption ranges: Expected life - ten years; stock price $0.114; volatility 35.13%; exercise price $0.11 and bond equivalent yield rate 1.47%. In December 2023, the Company and the consultant agreed to disengage and agreed to cancel the 1% option that the consultant held.

55000000

0.0001

539000

0.01 0.25

P6Y6M

0.0098

3.114

0.0001

0.0252

89883

449117

0.0001

P9Y9M29D

0.01

8081037

5000000

0.11

436908

0.05 0.50 0.50

0.114

0.3513

0.11

0.0147

NOTE 12 - EQUITY INCENTIVE PLAN On August 26, 2021, the Company adopted an equity incentive plan providing for the issuance of shares of common stock, options or SARs with a rolling maximum number equal to 10% of the issued and outstanding Common Shares set at the beginning of each fiscal year. The Company may grant incentives to its directors, officers, employees and service providers. The options are exercisable for a maximum of up to ten years from the date of grant and may be subject to vesting provisions as set by the Plan Administrator. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 12 - EQUITY INCENTIVE PLAN, continued During the quarter ended March 31, 2022, a total of 1,000,000 shares of common stock and 7,456,500 options at a weighted average exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zooVReNws4Yf">0.0518 per share exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0shGPTWSQii">five years with immediate vesting were granted to employees. The weighted-average fair value attributable to options granted in 2022 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zI5mu0hNzVD1">0.0517 per option. <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPJQur4RQVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of the stock options recognized in each year below was estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zab5JBFQ6O78" style="width: 16%; text-align: right" title="Risk-free interest rate">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zNvOFFQi64yl" style="width: 16%; text-align: right" title="Risk-free interest rate">1.55</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zAuXRdv79zR7" style="text-align: right" title="Exercise price">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zarE3PDEtUh5" style="text-align: right" title="Exercise price">0.0518</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_zHAn1XIrsLY5" style="text-align: right" title="Expected volatility">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zJJsGHLIPFGj" style="text-align: right" title="Expected volatility">307.11</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20230101__20231231_z078Cf6spgea" style="text-align: right" title="Expected dividends">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20220101__20221231_zkx7YeEDtV5g" style="text-align: right" title="Expected dividends">-</td><td style="text-align: left"> </td></tr> </table> The Company recognized equity incentive expense of $207,000 ($<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgZyuusQo9lc" title="Share-based payment arrangement, expense">51,750 for common shares and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zQ3A0Bcsjhlf" title="Share-based payment arrangement, expense">155,250 for the stock options) for the year ended December 31, 2022. As of December 31, 2023, there were 7,456,500 issued and outstanding equity incentive plan options which are all fully vested with a weighted average exercise price of $0.0518 per option and three years remaining life. At December 31, 2023, the closing market price of the stock was $0.0213 per share. A summary of the Company’s equity incentive plan options and changes during the year ended December 31, 2022, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance January 1, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znUFQXA0kuea" style="text-align: right" title="Number of options, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zUyOa0jh5Eud" style="text-align: right" title="Weighted Average Exercise Price, Beginning Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z7Tk1X4P7SM7" style="width: 16%; text-align: right" title="Number of options, Granted">7,456,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zPvd3Ux3v7Nk" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">0.0518</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z8Hh7eP6UoL3" style="text-align: right" title="Number of options,Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zaRiBfonv0Ma" style="text-align: right" title="Weighted Average Exercise Price,Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20221231_zgWhGBDj1sa2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zZnTKhgUGl23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Balance December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zqym6i4L1y7a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Beginning balance">7,456,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zZgp4bPztI34" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">0.0518</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">No activity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfOptionsNoActivity_c20230101__20231231_z4dIHGrZTZw5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, No activity">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zlInbMIbvOY4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Ending Balance">7,456,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zJsCvTusG5j5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">0.0518</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value of vested share options (the market value was less the exercise price) at December 31, 2023 and 2022 was zero.

1000000

7456500

0.0518

0.0517

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPJQur4RQVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of the stock options recognized in each year below was estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zab5JBFQ6O78" style="width: 16%; text-align: right" title="Risk-free interest rate">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zNvOFFQi64yl" style="width: 16%; text-align: right" title="Risk-free interest rate">1.55</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zAuXRdv79zR7" style="text-align: right" title="Exercise price">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zarE3PDEtUh5" style="text-align: right" title="Exercise price">0.0518</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_zHAn1XIrsLY5" style="text-align: right" title="Expected volatility">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zJJsGHLIPFGj" style="text-align: right" title="Expected volatility">307.11</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20230101__20231231_z078Cf6spgea" style="text-align: right" title="Expected dividends">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20220101__20221231_zkx7YeEDtV5g" style="text-align: right" title="Expected dividends">-</td><td style="text-align: left"> </td></tr> </table>

0.0155

0.0518

P5Y

3.0711

207000

51750

155250

7456500

0.0518

0.0213

A summary of the Company’s equity incentive plan options and changes during the year ended December 31, 2022, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance January 1, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znUFQXA0kuea" style="text-align: right" title="Number of options, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zUyOa0jh5Eud" style="text-align: right" title="Weighted Average Exercise Price, Beginning Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z7Tk1X4P7SM7" style="width: 16%; text-align: right" title="Number of options, Granted">7,456,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zPvd3Ux3v7Nk" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">0.0518</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z8Hh7eP6UoL3" style="text-align: right" title="Number of options,Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zaRiBfonv0Ma" style="text-align: right" title="Weighted Average Exercise Price,Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20221231_zgWhGBDj1sa2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zZnTKhgUGl23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Balance December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zqym6i4L1y7a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Beginning balance">7,456,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zZgp4bPztI34" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">0.0518</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">No activity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfOptionsNoActivity_c20230101__20231231_z4dIHGrZTZw5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, No activity">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zlInbMIbvOY4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Ending Balance">7,456,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zJsCvTusG5j5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">0.0518</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7456500

0.0518

7456500

0.0518

7456500

0.0518

NOTE 13 - FINANCIAL INSTRUMENTS (a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company’s capital stock to settle its liabilities when they become due. (b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary current assets and current liabilities. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022

NOTE 14 - GENERAL AND ADMINISTRATIVE EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 87%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zMGC4I5nfG7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zUn1lkGQ5Gfa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--Compensation_maGAAEzKSx_z7N1iHsJ5Fcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">947,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,260,685</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_maGAAEzKSx_zvGWHlyFJN98" style="vertical-align: bottom; background-color: White"> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298,558</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ProfessionalFee_maGAAEzKSx_zWTQoDnR63ij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,286</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherExpenses_maGAAEzKSx_zVkbr1555Nr2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,652</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">228,372</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_iT_mtGAAEzKSx_zFePJfmg7Npb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,565,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,958,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 87%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zMGC4I5nfG7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zUn1lkGQ5Gfa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--Compensation_maGAAEzKSx_z7N1iHsJ5Fcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">947,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,260,685</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_maGAAEzKSx_zvGWHlyFJN98" style="vertical-align: bottom; background-color: White"> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298,558</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ProfessionalFee_maGAAEzKSx_zWTQoDnR63ij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,286</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherExpenses_maGAAEzKSx_zVkbr1555Nr2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,652</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">228,372</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_iT_mtGAAEzKSx_zFePJfmg7Npb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,565,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,958,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 947333 1260685

187043

298558

126285 171286

304652

228372

1565313

1958901

NOTE 15 - IMPAIRMENT OF LONG-LIVED ASSETS In October 2022, the Company elected not to renew patent rights option for US Patent No 8,287,505 Ophthalmic Drop Dispensing Tip Assembly and expensed the $3,800 cost basis of this option.

3800

NOTE 16 - INCOME TAXES The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized. The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zytRGFt3DEP2" style="border-bottom: Black 1.5pt solid; text-align: center"> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zfYC7xfIkjme" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzXHG_zyMhdWSwHBy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzXHG_zfzBAi7mCbl4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzXHG_z91okDuxH9ha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total tax provisions</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_z29AaebrHyp6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zrFeCCTAMYk5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR001_zCfBHfGsvhJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">U.S. Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR001_zhxX46o48sLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">State income tax, net of federal benefit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateContinuingOperationsBeforeDeduction_pid_dp_mtETR001_ma1_zyc044ph0Aka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationValuationAllowance_iN_pid_dpi_ms1_zgKlKWkt1d1h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mt1_zzwdZAY461v8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 16 - INCOME TAXES, continued The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zM4z7QE37lQb" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zvrXzfBChPYg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz4T0_zeaZ7X7fSYN" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,413,633</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,424,882</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz4T0_z450g1gbVj7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,956,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,899,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTAGz4T0_zSZwzZAFeqVc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">700,621</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">645,379</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzW1K_mtDTAGz4T0_zQLXCLqo9eVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,972,221</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,969,367</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzW1K_zAkgqdtWO7Pi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,972,221</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,969,367</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzW1K_zsxcRQqg3TUe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The change in valuation allowance was ($1,002,854) and ($1,930,167) for the years ended December 31, 2023, and 2022, respectively. We have recorded a 100% valuation allowance related to the deferred tax asset for the income from operations. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2023 and 2022, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zytRGFt3DEP2" style="border-bottom: Black 1.5pt solid; text-align: center"> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zfYC7xfIkjme" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzXHG_zyMhdWSwHBy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzXHG_zfzBAi7mCbl4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzXHG_z91okDuxH9ha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total tax provisions</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_z29AaebrHyp6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zrFeCCTAMYk5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR001_zCfBHfGsvhJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">U.S. Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR001_zhxX46o48sLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">State income tax, net of federal benefit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateContinuingOperationsBeforeDeduction_pid_dp_mtETR001_ma1_zyc044ph0Aka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationValuationAllowance_iN_pid_dpi_ms1_zgKlKWkt1d1h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25.35</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mt1_zzwdZAY461v8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

0.210

0.0435

0.2535 0.2535 0.2535 0.2535

0.000

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zM4z7QE37lQb" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zvrXzfBChPYg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz4T0_zeaZ7X7fSYN" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,413,633</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,424,882</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz4T0_z450g1gbVj7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,956,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,899,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTAGz4T0_zSZwzZAFeqVc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">700,621</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">645,379</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzW1K_mtDTAGz4T0_zQLXCLqo9eVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,972,221</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,969,367</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzW1K_zAkgqdtWO7Pi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,972,221</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,969,367</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzW1K_zsxcRQqg3TUe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3413633

2424882

1956967

1899106

700621

645379

5972221

4969367

5972221

4969367

1002854

1930167

NOTE 17 - COMMITMENTS AND CONTINGENCIES The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations.

NOTE 18 - CONCENTRATIONS OF CREDIT RISK (a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had zero cash balance in excess of FDIC insured limits at December 31, 2023 and 2022.

NOTE 19 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022

NOTE 20 - SUBSEQUENT EVENTS Management has evaluated subsequent events and transactions for potential recognition or disclosure in the financial statements through April 30, 2024, the date these financial statements were available to be issued. (a) Senior Secured Note In January 2024, The Company and the lender agreed to the 16th modification of the Note. In exchange for receipt of $<span id="xdx_904_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zJnSRMK1xore" title="Accrued interest">15,000 of accrued interest and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zrnvxQ2rpAY" title="Warrants to purchase shares">4,571,429 additional warrants for the modification, the maturity date was extended to <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zel0Ifmexmhk" title="Maturity date">April 2, 2024. This modification allows for a further extension to <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zQWLaphVowM7" title="Maturity date">May 2, 2024, at the option of the Company in exchange for payment of $<span id="xdx_90C_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zYp2urznamT5" title="Accrued interest">10,000 of accrued interest and an additional <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zbsxCxo0XbI5" title="Warrants to purchase shares">1,142,857 warrants. On March 25, 2024, the Company exercised the option to extend this note to May 2, 2024. (b) Related party short term notes payable In January 2024, the lender agreed to an extension of the maturity dates of these notes to May 15, 2024. (c ) Note payable In January 2024, the note was extended to <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zdVTyFVwdXVk" title="Maturity date">May 31, 2024, upon the payment of a $6,000 late fee by February 1, 2024, and $6,250 for accrued interest and a $250 late fee by February 29, 2024. (d) Deficiency in Stockholders Equity In the first quarter, 2024, the Company issued <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHH4sKUN92o8" title="Shares issued">252,750 shares of Series B preferred stock in exchange for $<span id="xdx_90E_eus-gaap--Cash_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwfkQr8hh8Y7" title="Cash">227,750 in cash and $<span id="xdx_90F_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCPy07Z7kID3" title="Subscriptions receivable">25,000 subscription receivable. In the first quarter 2024, the Company received the $115,625 of subscriptions receivable. (e) Intangible Assets National Institute of Health (NIH) Patent License #2. In January 2024, the Company negotiated a 14-month extension of the right to extend the license to the remaining life of the licensed patent in exchange for a license extension fee in the amount of $5,000. (f) Accounts payable In March 2024, the Company entered into a payment plan to pay $48,318 per month for 24 months to satisfy an outstanding amount of $<span id="xdx_90B_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zW0G8Thiakl5">1,159,637 to one vendor.

15000

4571429

2024-04-02

2024-05-02

10000

1142857

2024-05-31

6000

6250

250

252750

227750

25000

115625

5000

48318

1159637

NOTE 21 - REVERSE STOCK SPLIT (UNAUDITED) On September 26, 2022, the Company filed an amendment to its amended and restated articles of incorporation with the Secretary of State of the State of Florida (the “Secretary of State”) to effect a reverse stock split at a ratio of 1-for-400. While the amendment was approved by the Secretary of State, the Company’s Common Stock has not yet begun trading on a reverse stock split basis. The reverse split will be effected following the effectiveness of the registration statement on Form S-1 and the conversion of all of the Series B and Series C preferred stock and approval for trading on the NYSE/AMEX trading market and prior to the completion of the offering contemplated by the S-1. <p id="xdx_89B_ecustom--ScheduleOfProFormaEffectOfReverseStockSplitOnBasicAndDilutedNetLossPerShareTableTextBlock_zOVSqBxGHrlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following is the unaudited pro-forma effect of the 1:400 reverse stock split on the basic and diluted net loss per share: SCHEDULE OF PRO-FORMA EFFECT OF REVERSE STOCK SPLIT ON BASIC AND DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Historical per share data- pre-split basis</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zbRdbmMZzlNl" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,817,253</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zdc8kjalozl7" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,468,684</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zebws00aghR4" title="Basic weighted average shares outstanding"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zCqHszgkLWX2" title="Diluted weighted average shares outstanding">662,161,949</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zpgwnSC5G2" title="Basic weighted average shares outstanding"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zB9nNsCpQHue" title="Diluted weighted average shares outstanding">572,009,911</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 21 - REVERSE STOCK SPLIT (UNAUDITED), continued <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Historical per share data- post-split basis - UNAUDITED</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zKe6glfrrkAb" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,817,253</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zuCfD3w26qni" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,468,684</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zFiJvu2tCmL5" title="Basic weighted average shares outstanding"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zW8mmaveJesc" title="Diluted weighted average shares outstanding">1,655,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zzhpBFnlJUh2" title="Basic weighted average shares outstanding"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zAc185Kcw8Se" title="Diluted weighted average shares outstanding">1,430,025</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.82</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_897_ecustom--ScheduleOfProFormaEffectOfConversionOfPreferredStockAndReverseStockSplitOnBalanceSheetTableTextBlock_zGCjJYrPFCM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">The following is the unaudited pro-forma effect of the conversion of Series B and C preferred stock and the 1:400 reverse stock split on the balance sheet: SCHEDULE OF PRO-FORMA EFFECT OF CONVERSION OF PREFERRED STOCK AND REVERSE STOCK SPLIT ON THE BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_z1AzKhw6XCJ7" style="border-bottom: Black 1.5pt solid; text-align: center"> December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--StatementEquityComponentsAxis__custom--ConversionOfSeriesBAndCPreferredStockMember_zd6MzwLkHzFa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Conversion of Series B and C Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231__srt--RestatementAxis__custom--OneToOneThousandFourHundredAdjustmentMember_zT7YJsqR0sie" style="border-bottom: Black 1.5pt solid"> 1:400 Adjustment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20231231__srt--StatementScenarioAxis__srt--ProFormaMember_zyq7EazjJdr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro-Forma Effect December 31, 2023 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_zSDZOGFSZVld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,603,196</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,603,196</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_maLASEzzxb_z3eYZtPDovHa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,745,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,745,821</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--StockholdersEquityAbstract_iB_zlTCC24JWUm4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deficiency in Stockholder’s Equity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zw2xBHxScqt6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(75</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zC9pkm1TdwSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series C Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzCdU_zQM9LWwUBFj2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CommonStockValue_i01I_maSEzCdU_zAb4VBfIQYJ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(138,653</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">348</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i01I_maSEzCdU_zwXrrFhQjeIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additional paid-in Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,994,471</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(46,200</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,086,924</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzCdU_znfC3OWvgSS7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,229,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,229,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--StockholdersEquity_i01TI_mtSEzCdU_maLASEzzxb_zapaDbdAP06" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,142,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,142,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzzxb_zaGXuL7iLb11" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities and Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,603,196</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,603,196</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 21 - REVERSE STOCK SPLIT (UNAUDITED), continued <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zvz8Ctl5B4lg" style="border-bottom: Black 1.5pt solid; text-align: center"> December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--StatementEquityComponentsAxis__custom--ConversionOfSeriesBAndCPreferredStockMember_z7SDTmEf8nDc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Conversion of Series B and C Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231__srt--RestatementAxis__custom--OneToOneThousandFourHundredAdjustmentMember_z8zY1v1dnCxe" style="border-bottom: Black 1.5pt solid"> 1:400 Adjustment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20221231__srt--StatementScenarioAxis__srt--ProFormaMember_zKVVZdRyyn6c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro-Forma Effect December 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_zNoGKdVgrUf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,061,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,061,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_maLASEzzxb_zJmWKxAt1DGd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,600,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,600,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--StockholdersEquityAbstract_iB_zjyVDGIvTmca" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Deficiency in Stockholder’s Equity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNlL47fygQT3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zSJJCSDBwePf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series C Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzCdU_zWPUTBrwN9Mi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockValue_i01I_maSEzCdU_zzE8tWBuXrb6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,453</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(85,166</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i01I_maSEzCdU_zhKu8LOucTG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additional paid-in Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,813,351</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,433</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,874,084</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzCdU_zP8PmDloXQw1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,412,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,412,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--StockholdersEquity_i01TI_mtSEzCdU_maLASEzzxb_zODBpjbWshI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,538,346</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,538,346</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzzxb_z0JZxQ078Q0l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities and Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,061,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,061,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

a reverse stock split at a ratio of 1-for-400.

<p id="xdx_89B_ecustom--ScheduleOfProFormaEffectOfReverseStockSplitOnBasicAndDilutedNetLossPerShareTableTextBlock_zOVSqBxGHrlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following is the unaudited pro-forma effect of the 1:400 reverse stock split on the basic and diluted net loss per share: SCHEDULE OF PRO-FORMA EFFECT OF REVERSE STOCK SPLIT ON BASIC AND DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Historical per share data- pre-split basis</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zbRdbmMZzlNl" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,817,253</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zdc8kjalozl7" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,468,684</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zebws00aghR4" title="Basic weighted average shares outstanding"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zCqHszgkLWX2" title="Diluted weighted average shares outstanding">662,161,949</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zpgwnSC5G2" title="Basic weighted average shares outstanding"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPreSplitBasisMember_zB9nNsCpQHue" title="Diluted weighted average shares outstanding">572,009,911</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 21 - REVERSE STOCK SPLIT (UNAUDITED), continued <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Historical per share data- post-split basis - UNAUDITED</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss available to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zKe6glfrrkAb" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,817,253</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zuCfD3w26qni" style="width: 18%; text-align: right" title="Net loss available to common shareholders">(5,468,684</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zFiJvu2tCmL5" title="Basic weighted average shares outstanding"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zW8mmaveJesc" title="Diluted weighted average shares outstanding">1,655,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zzhpBFnlJUh2" title="Basic weighted average shares outstanding"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__srt--StatementScenarioAxis__custom--ReverseStockSplitPostSplitBasisMember_zAc185Kcw8Se" title="Diluted weighted average shares outstanding">1,430,025</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.82</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-5817253

-5468684

662161949

572009911

-0.01

-5817253

-5468684

1655405

1430025

-3.51

-3.82

<p id="xdx_897_ecustom--ScheduleOfProFormaEffectOfConversionOfPreferredStockAndReverseStockSplitOnBalanceSheetTableTextBlock_zGCjJYrPFCM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">The following is the unaudited pro-forma effect of the conversion of Series B and C preferred stock and the 1:400 reverse stock split on the balance sheet: SCHEDULE OF PRO-FORMA EFFECT OF CONVERSION OF PREFERRED STOCK AND REVERSE STOCK SPLIT ON THE BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_z1AzKhw6XCJ7" style="border-bottom: Black 1.5pt solid; text-align: center"> December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--StatementEquityComponentsAxis__custom--ConversionOfSeriesBAndCPreferredStockMember_zd6MzwLkHzFa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Conversion of Series B and C Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231__srt--RestatementAxis__custom--OneToOneThousandFourHundredAdjustmentMember_zT7YJsqR0sie" style="border-bottom: Black 1.5pt solid"> 1:400 Adjustment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20231231__srt--StatementScenarioAxis__srt--ProFormaMember_zyq7EazjJdr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro-Forma Effect December 31, 2023 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_zSDZOGFSZVld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,603,196</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,603,196</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_maLASEzzxb_z3eYZtPDovHa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,745,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,745,821</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--StockholdersEquityAbstract_iB_zlTCC24JWUm4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deficiency in Stockholder’s Equity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zw2xBHxScqt6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(75</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zC9pkm1TdwSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series C Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzCdU_zQM9LWwUBFj2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CommonStockValue_i01I_maSEzCdU_zAb4VBfIQYJ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(138,653</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">348</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i01I_maSEzCdU_zwXrrFhQjeIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additional paid-in Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,994,471</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(46,200</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,086,924</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzCdU_znfC3OWvgSS7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,229,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,229,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--StockholdersEquity_i01TI_mtSEzCdU_maLASEzzxb_zapaDbdAP06" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,142,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,142,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzzxb_zaGXuL7iLb11" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities and Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,603,196</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,603,196</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements December 31, 2023 and 2022 NOTE 21 - REVERSE STOCK SPLIT (UNAUDITED), continued <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zvz8Ctl5B4lg" style="border-bottom: Black 1.5pt solid; text-align: center"> December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--StatementEquityComponentsAxis__custom--ConversionOfSeriesBAndCPreferredStockMember_z7SDTmEf8nDc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Conversion of Series B and C Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231__srt--RestatementAxis__custom--OneToOneThousandFourHundredAdjustmentMember_z8zY1v1dnCxe" style="border-bottom: Black 1.5pt solid"> 1:400 Adjustment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20221231__srt--StatementScenarioAxis__srt--ProFormaMember_zKVVZdRyyn6c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro-Forma Effect December 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_zNoGKdVgrUf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,061,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">2,061,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_maLASEzzxb_zJmWKxAt1DGd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,600,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,600,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--StockholdersEquityAbstract_iB_zjyVDGIvTmca" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Deficiency in Stockholder’s Equity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNlL47fygQT3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zSJJCSDBwePf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series C Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzCdU_zWPUTBrwN9Mi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockValue_i01I_maSEzCdU_zzE8tWBuXrb6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,453</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(85,166</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i01I_maSEzCdU_zhKu8LOucTG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additional paid-in Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,813,351</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,433</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,874,084</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzCdU_zP8PmDloXQw1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,412,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,412,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--StockholdersEquity_i01TI_mtSEzCdU_maLASEzzxb_zODBpjbWshI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,538,346</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,538,346</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzzxb_z0JZxQ078Q0l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities and Deficiency in Stockholder’s Equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,061,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,061,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2603196

5745821

-75

2400

-2400

2400

-2400

90326

48675

-138653

348

34994471

-46200

138653

35086924

-38229897

-3142625

2603196

2061915

4600261

-20

3000

-3000

3000

-3000

57927

27453

-85166

214

29813351

-24433

85166

29874084

-32412644

-2538346

2061915